Ellipses Pharma: Clinical Trials

4 trials sponsored by Ellipses Pharma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 recruiting, 1 not yet recruiting. 4 Phase 1, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 14Recruiting 3, Not yet recruiting 1
Phase 24Recruiting 3, Not yet recruiting 1

Follow Ellipses Pharma: new trials by email

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Safety and Tolerability of EP0089
EP0089-101 - Solid Cancers, Solid Tumours
Phase 1 / Phase 2Not yet recruitingEllipses Pharma1902025-09-012025-06-22
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
EP0062, Elacestrant, Everolimus - Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer
Phase 1 / Phase 2RecruitingEllipses Pharma952023-01-112026-06-22
A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies
EP0031, Platinum chemotherapy, Pemetrexed - NSCLC
Phase 1 / Phase 2RecruitingEllipses Pharma2652022-09-302026-07-01
Study to Evaluate the Safety and Tolerability of EP0042
EP0042, Venetoclax, Azacitidine (AZA) - Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Phase 1 / Phase 2RecruitingEllipses Pharma702020-11-022026-06-22

Conditions studied

Breast Neoplasms (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Leukemia, Myelomonocytic, Chronic (1)  ·  Myelodysplastic Syndromes (1)

Interventions

Azacitidine (1)  ·  Everolimus (1)  ·  Fulvestrant (1)  ·  Pemetrexed (1)  ·  abemaciclib (1)  ·  elacestrant (1)  ·  exemestane (1)  ·  venetoclax (1)

Countries

United Kingdom (3)  ·  Spain (2)  ·  United States (2)  ·  Australia (1)  ·  France (1)  ·  Germany (1)  ·  Italy (1)  ·  Netherlands (1)  ·  Poland (1)  ·  United Arab Emirates (1)

Top investigators

David Taussig (1)